Results 241 to 250 of about 47,442 (285)
In vitro and in vivo disease models of cardiac amyloidosis: progress, pitfalls, and potential. [PDF]
Cardiovasc ResQin J +10 more
europepmc +1 more source
Echocardiography in Cardiac Amyloidosis: From Identification to Classification. [PDF]
JACC AsiaLiang S, Huang H, Chen Y.
europepmc +1 more source
Cardiac involvement in familial amyloidosis with polyneuropathy
, 1984 Peter Eriksson
openalex +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Treatment Options in Cardiovascular Medicine, 1999
No definitive therapy is available for cardiac amyloidosis. Treatment with alkylating agents such as melphalan has improved survival. Patients who do not respond to melphalan have benefited from high-dose chemotherapy with cyclophosphamide followed by peripheral stem cell transplantation.
, Kashyap, , Hosenpud
openaire +4 more sources
No definitive therapy is available for cardiac amyloidosis. Treatment with alkylating agents such as melphalan has improved survival. Patients who do not respond to melphalan have benefited from high-dose chemotherapy with cyclophosphamide followed by peripheral stem cell transplantation.
, Kashyap, , Hosenpud
openaire +4 more sources
Expert Review of Cardiovascular Therapy, 2014
Amyloidosis is a condition characterized by the extracellular deposition of insoluble fibrillar protein in tissues and various organs including the heart. This review summarizes the clinical manifestations and diagnostic treatment approaches for cardiac amyloidosis.
Syed Wamique, Yusuf +7 more
openaire +2 more sources
Amyloidosis is a condition characterized by the extracellular deposition of insoluble fibrillar protein in tissues and various organs including the heart. This review summarizes the clinical manifestations and diagnostic treatment approaches for cardiac amyloidosis.
Syed Wamique, Yusuf +7 more
openaire +2 more sources
Cardiac transthyretin amyloidosis
Heart, 2012Cardiac amyloidosis of transthyretin fibril protein (ATTR) type is an infiltrative cardiomyopathy characterised by ventricular wall thickening and diastolic heart failure. Increased access to cardiovascular magnetic resonance imaging has led to a marked increase in referrals to our centre of Caucasian patients with wild-type ATTR (senile systemic ...
Jason N, Dungu +3 more
openaire +2 more sources
American Heart Journal, 1953
Abstract Two cases of amyloidosis limited to the heart and one case of amyloidosis involving the heart and lungs are reported. All three patients were men in, or close to, the ninth decade of life. In all three cases auricular fibrillation and congestive failure were present. The literature is reviewed and a distinction drawn between systemic primary
A I, THOMASHOW +2 more
openaire +2 more sources
Abstract Two cases of amyloidosis limited to the heart and one case of amyloidosis involving the heart and lungs are reported. All three patients were men in, or close to, the ninth decade of life. In all three cases auricular fibrillation and congestive failure were present. The literature is reviewed and a distinction drawn between systemic primary
A I, THOMASHOW +2 more
openaire +2 more sources
Transthyretin Cardiac Amyloidosis
Current Cardiology Reports, 2017Transthyretin (TTR)-related cardiac amyloidosis is a progressive infiltrative cardiomyopathy that mimics hypertensive, hypertrophic heart disease and may go undiagnosed. Transthyretin-derived amyloidosis accounts for 18% of all cases of cardiac amyloidosis.
Anit K, Mankad, Keyur B, Shah
openaire +2 more sources